Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →

Early-stage triple-negative breast cancer with separate lung carcinoid and later CML

Patient Info: Anonymized, Female, 50s

Biomarkers: triple negative

As of May 2025, serial follow-up breast ultrasound examinations showed no evidence of breast cancer recurrence in either breast tissue or axillary lymph nodes.

PubMed CentralRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

Stage 0 Invasive Lobular Carcinoma: Kathleen's Survivor Story

Patient Info: Kathleen, Female | Stage 0

Kathleen completed surgery-focused treatment for DCIS with a very small invasive lobular component. No chemotherapy was needed, endocrine therapy was discussed but not required, and she continued imaging surveillance and advocacy in the flat community.

The Patient StoryRead more →

Breast cancer linked to a rare kidney condition believed to be cancer-related

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2 score 1+; Ki-67 5-10%

At the latest follow-up, she had no local or distant breast-cancer recurrence and maintained excellent performance status.

PubMed CentralRead more →

Breast cancer history: atypical pelvic fracture after long-term zoledronic acid

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Prior breast cancer treatment had been completed; CT during fracture evaluation showed no metastatic disease, and the atypical iliac wing fracture healed progressively with conservative care and teriparatide.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Katie's Patient Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

As of February 2025, Katie was a few months beyond active treatment for Stage III ER-positive, PR-positive, HER2-negative ILC and was adjusting to maintenance therapy with Verzenio, Lupron, and Letrozole.

Lobular Breast Cancer AllianceRead more →

Metastatic Breast Cancer Returning About 20 Years After Initial Treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones

About 20 years after her original breast-cancer treatment and sustained remission, bone biopsy confirmed metastatic recurrence; she became too unwell for planned cancer therapy and chose supportive care.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Stage IV luminal B HER2-negative breast cancer with liver-limited metastasis resected after systemic therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Luminal B; HER2-negative

Metastatic Site: liver

After liver segmentectomy for breast-cancer liver metastasis, follow-up imaging showed no remaining liver nodes, and she remained fit, well, disease-free, and on maintenance letrozole plus goserelin.

PubMed CentralRead more →

Stage IV luminal A breast cancer: liver resection and disease-free follow-up

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: luminal A; ER-positive; PgR-positive; HER2-negative

Metastatic Site: lung, liver

Disease-free after R0 hepatic segmentectomy for breast cancer liver metastasis, with May 2021 MRI showing no remaining liver nodules while she continued maintenance letrozole and goserelin.

PubMed CentralRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Stage IV luminal B breast cancer with liver, bone, and bone marrow metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 20% positive; HER2-negative; Ki-67 60%; luminal B

Metastatic Site: liver, bone, bone marrow

The patient had marked clinical and hematologic improvement on leuprorelin, letrozole, ribociclib, and zoledronic acid, with sustained complete remission reported for 4 months from September to December 2023 and monthly follow-up advised.

PubMed CentralRead more →

Breast Cancer and a Separate Intrahepatic Cholangiocarcinoma in a 35-Year-Old Woman

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-positive, HER2/CerbB-2 positive

Breast-cancer care continued with postoperative endocrine maintenance while a separate primary intrahepatic cholangiocarcinoma required additional treatment.

PubMed CentralRead more →

Stage IIIA HR-positive HER2-negative breast cancer with radiation-induced brachial plexopathy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: HR-positive/HER2-negative breast cancer with pathogenic ATM and PALB2 variants plus an ATM VUS.

Approximately 3.5 years after radiation therapy, there was no evidence of breast cancer recurrence, but severe radiation-induced brachial plexopathy, fibrosis, telangiectasias, and lymphedema-related symptoms required ongoing supportive care.

PubMed CentralRead more →

Metastatic Male Breast Cancer Responding to Abemaciclib and Letrozole

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: soft tissue, distant lymph nodes, bone

The tumor and metastatic soft-tissue and lymph-node disease shrank markedly, with no progression on July 2024 imaging and good clinical condition in September 2024.

PubMed CentralRead more →

Severe Corneal Injury After Trastuzumab for Metastatic HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: lungs, spine, left adrenal gland, calvarium, orbit,…

She was living with widespread metastatic breast cancer when trastuzumab was stopped because of severe eye toxicity.

PubMed CentralRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee Doherty, Female, Under 40 | Stage IV

Biomarkers: Hormone-sensitive disease implied by letrozole and ovarian suppression; ER/PR/HER2 status not explicitly stated

Metastatic Site: bone

As of September 2024, Dee was living with Stage IV metastatic breast cancer. Her tumors had not shrunk, but disease was stable on ribociclib/Kisqali, letrozole, and ovarian suppression.

The Patient StoryRead more →

Stage 4 breast cancer: complete remission with letrozole and palbociclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Breast cancer was ER/PR positive, HER2 0

Metastatic Site: pleura/pleural effusion

Breast cancer remained in remission on letrozole after palbociclib was stopped; Ph-positive B-ALL achieved complete response with no molecular residual disease after blinatumomab plus ponatinib, with ongoing monthly outpatient monitoring.

PubMed CentralRead more →

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed CentralRead more →

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed CentralRead more →

BRCA2-mutant metastatic breast cancer: complete response with rucaparib maintenance

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Germline BRCA2 mutation; somatic BRCA2 mutation; HER2 amplification not seen by FISH; grade III IDC

Metastatic Site: bone

She maintained a complete response for 2 years on rucaparib, letrozole, and zoledronic acid after upfront metastatic BRCA2-mutated breast cancer involving bone, axillary nodes, and right-breast nodules.

PubMed CentralRead more →